Infinite: IVUS VS CAG Guided PCI for Patients With LMB Lesion

Sponsor
Shanghai Zhongshan Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04072003
Collaborator
(none)
616
48

Study Details

Study Description

Brief Summary

To compare the 3 - year clinical follow - up results of patients with left main bifurcation lesions treated by intravascular ultrasound(IVUS) - guided and coronary angiography(CAG) - guided percutaneous coronary intervention(PCI), and to confirm the clinical benefits of optimizing interventional therapy of left main bifurcation lesions by intravascular ultrasound(IVUS).

Condition or Disease Intervention/Treatment Phase
  • Device: intravascular ultrasound (IVUS)
  • Other: coronary angiography

Detailed Description

616 patients with primary left main coronary artery bifurcation lesions will be recruited in this study. The target lesions of patients need to be true coronary artery bifurcation lesions (Medina 1,1,1 or 0,1,1). After angiography, patients will be randomly assigned to intravascular ultrasound(IVUS) - guided and coronary angiography (CAG)- guided groups. The random number of patients will be generated by the central computer random system, and the random will be stratified according to the study sites. In coronary angiography(CAG)-guided group, two-stent technique will be used(the exact two-stent technique used was left to the operator's discretion). In intravascular ultrasound(IVUS)-guided group, minimal lumen area(MLA) in ostium of side branch will be measured by intravascular ultrasound(IVUS). If minimal lumen area(MLA)<4mm2, two-stent technique will be used(the exact two-stent technique used was left to the operator's discretion) and intravascular ultrasound(IVUS) will be repeated at the end of the procedure. If minimal lumen area(MLA) >=4mm2, one-stent technique will be used and intravascular ultrasound(IVUS) will be repeated. If minimal lumen area(MLA) in ostium of side branch is still >=4mm2, the procedure will be ended. If minimal lumen area(MLA) in ostium of side branch become <4mm2, the following interventional strategy will be left to the operator's discretion( balloon inflation, drug-eluting balloon, or switch to two-stent technique). Again, intravascular ultrasound(IVUS) will be repeated at the end of the procedure.

Study Design

Study Type:
Observational
Anticipated Enrollment :
616 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Intravascular Ultrasound(IVUS) vs Angiography Guided Percutaneous Coronary Intervention(PCI) for Patients With Left Main Bifurcation Lesion
Anticipated Study Start Date :
Sep 1, 2019
Anticipated Primary Completion Date :
Sep 1, 2021
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
IVUS-guided PCI

In this group, intravascular ultrasound(IVUS) in addition to coronary angiography(CAG) is used to guide percutaneous coronary intervention(PCI) procedure of left main bifurcation lesion.

Device: intravascular ultrasound (IVUS)
use IVUS in the procedure

Other: coronary angiography
Coronary angiography is required for all PCI procedure.

CAG-guided PCI

In this group, coronary angiography(CAG) is used to guide percutaneous coronary intervention(PCI) procedure of left main bifurcation lesion.

Other: coronary angiography
Coronary angiography is required for all PCI procedure.

Outcome Measures

Primary Outcome Measures

  1. Target vessel failure rate(the rate of outcomes including cardiac death, target vessel myocardial infarction(MI), and clinically driven main branch or side branch target vessel revascularization(TVR) in each group) [12th month after stent implantation]

    Cardiac death is defined as death resulting from an acute myocardial infarction (MI), sudden cardiac death, stroke, death due to heart failure (HF), death due to cardiovascular (CV) procedures, death due to CV hemorrhage, and death due to other CV causes; target vessel MI is defined as a MI case with the evidence of myocardial necrosis in the vascular territory of previously treated vessel; clinically driven main branch or side branch TVR is defined as a revascularization procedure with repeated stenting, balloon angioplasty or surgical bypass grafting for restenosed or occluded culprit target vessel.

Secondary Outcome Measures

  1. major adverse cardiac and cerebrovascular events(MACCE)rate( the percentage of outcomes including all cause death, stroke, myocardial infarction(MI), and all clinically driven target vessel revascularization(TVR) in each group) [30 days, 6 months, 12 months, 24 months and 36 months after operation]

    TVR is defined as a revascularization procedure with repeated stenting, balloon angioplasty or surgical bypass grafting for restenosed or occluded culprit target vessel.

  2. The percentage of in-stent restenosis (ISR) assessed by quantitative coronary angiography(QCA) in each group [12 months after operation]

    ISR is defined as a >50% stenosis of a previously stented segment as judged by QCA after coronary angiography

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients with stable or unstable angina pectoris, asymptomatic myocardial ischemia or attack of myocardial infarction >24 h;

  2. True bifurcation lesion of left main coronary artery (Medina 1,1,1 or 0,1,1);

  3. According to coronary angiography, the opening stenosis of the left anterior descending (LAD) and left circumflex (LCX) is more than 50% visually;

  4. The operator judges that the lesion is suitable for drug eluting stent(DES) implantation;

  5. Branch vessel diameter ≥2.5 mm by visual inspection;

Exclusion Criteria:
  1. Pregnant or lactating women;

  2. Combined with other diseases, life expectancy <1 year;

  3. A surgery is scheduled within 6 months after the operation, and this surgery affects continuous administration of antiplatelet drugs;

  4. The dual antiplatelet therapy cannot be tolerated;

  5. Follow - up visits required by the protocol cannot be followed, or the investigators believe that the participation of subjects in the trial will increase the risk;

  6. Unable to provide written informed consent form, or unable to follow the trial protocol;

  7. Participate in another clinical trial of coronary interventional device;

  8. Subjects with myocardial infarction within 24 h of onset of chest pain (including ST segment elevation or non - ST segment elevation);

  9. Suffer from renal failure requiring dialysis treatment or is undergoing dialysis treatment;

  10. Hemoglobin <9 g/L;

  11. Uncontrolled hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥ 110 mmHg);

  12. Severe cardiac insufficiency (LVEF <30%);

  13. Heart failure complicated with pulmonary hypertension (mean pulmonary artery pressure(mPAP) ≥25 mmHg,pulmonary capillary wedge pressure (PCWP) >15 mmHg, and pulmonary vascular resistance (PVR)>3.0WU);

  14. Complicated with hypertrophic obstructive cardiomyopathy;

  15. Re-stenotic bifurcation lesion;

  16. Severe calcified lesions requiring rotational atherectomy;

  17. Chronic total occlusion lesion without successful recanalization;

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Shanghai Zhongshan Hospital

Investigators

  • Principal Investigator: Junbo Ge, Fudan University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Junbo Ge, Head of department of Cardiology, Zhongshan hospital, principal investigator, clinical professor, Shanghai Zhongshan Hospital
ClinicalTrials.gov Identifier:
NCT04072003
Other Study ID Numbers:
  • B2018246
First Posted:
Aug 28, 2019
Last Update Posted:
Aug 28, 2019
Last Verified:
Aug 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Junbo Ge, Head of department of Cardiology, Zhongshan hospital, principal investigator, clinical professor, Shanghai Zhongshan Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 28, 2019